Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Company profile
Ticker
IMPL
Exchange
Website
CEO
Michael Hite
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
IMPEL NEUROPHARMA INC
SEC CIK
Corporate docs
Subsidiaries
Impel NeuroPharma Australia PTY LTD ...
IRS number
263058238
IMPL stock data
News
Earnings Outlook For Impel NeuroPharma
12 Aug 22
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
19 Jul 22
Impel Commences Mid-Stage Autism Spectrum Disorder Study
19 Jul 22
Impel NeuroPharma's Return On Capital Employed Insights
21 Jun 22
Impel Pharmaceuticals: Q1 Earnings Insights
16 May 22
Investment data
Securities sold
Number of investors
Calendar
16 May 22
12 Aug 22
26 Apr 23
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 129.84M | 129.84M | 129.84M | 129.84M | 129.84M | 129.84M |
| Cash burn (monthly) | (no burn) | (no burn) | 8.99M | 7.68M | 8.07M | 6.72M |
| Cash used (since last report) | n/a | n/a | 39.74M | 33.97M | 35.67M | 29.71M |
| Cash remaining | n/a | n/a | 90.1M | 95.87M | 94.16M | 100.12M |
| Runway (months of cash) | n/a | n/a | 10.0 | 12.5 | 11.7 | 14.9 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Jun 22 | David D. Allison | Stock Option Common Stock | Grant | Acquire A | No | No | 8.65 | 12,789 | 110.62K | 12,789 |
| 16 Jun 22 | Parker H Stewart | Stock Option Common Stock | Grant | Acquire A | No | No | 8.65 | 12,789 | 110.62K | 12,789 |
| 16 Jun 22 | Timothy S Nelson | Stock Option Common Stock | Grant | Acquire A | No | No | 8.65 | 12,789 | 110.62K | 12,789 |
| 16 Jun 22 | Mahendra Shah | Stock Option Common Stock | Grant | Acquire A | No | No | 8.65 | 12,789 | 110.62K | 12,789 |
| 16 Jun 22 | Wilfong Diane E. | Stock Option Common Stock | Grant | Acquire A | No | No | 8.65 | 12,789 | 110.62K | 12,789 |
Institutional ownership, Q1 2022
| 13F holders | Current |
|---|---|
| Total holders | 46 |
| Opened positions | 5 |
| Closed positions | 8 |
| Increased positions | 13 |
| Reduced positions | 12 |
| 13F shares | Current |
|---|---|
| Total value | 272.63M |
| Total shares | 26.78M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Kohlberg Kravis Roberts & Co. | 4.14M | $26.35M |
| KKR Iris Investors | 3.8M | $57.23M |
| 5AM Venture Management | 2.88M | $18.38M |
| Vivo Capital VIII | 2.88M | $43.42M |
| Vivo Capital | 2.88M | $18.38M |
| venBio Global Strategic Fund II | 2.76M | $41.54M |
| venBio Partners | 2.76M | $17.58M |
| 5AM Ventures V | 2.31M | $34.76M |
| Vanguard | 531.78K | $3.39M |
| DCF Advisers | 367.06K | $2.34M |
Financial report summary
?Competition
Acorda Therapeutics • Abbvie • Zosano Pharma • Satsuma Pharmaceuticals • Amneal PharmaceuticalsContent analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
Academy, Africa, aimed, arrangement, assumption, bifurcated, bifurcation, Brazil, Britain, Canada, captioned, car, Carlo, Chairman, compound, embedded, estate, expedient, exploring, fixed, fleet, floor, fourth, France, geopolitical, Germany, Great, half, highlighted, hoc, Hong, host, implicit, impute, imputed, inaugural, India, instability, intercreditor, intermittent, Israel, Japan, Kong, Korea, Mexico, mild, military, monetization, Monte, multiplied, Neurology, Oaktree, occupy, Overnight, pain, peer, penetrate, perfected, playing, ranking, real, recipient, reclassification, refill, repay, repeat, repurchase, rescinding, residual, RIF, role, ROU, royalty, RSU, Russia, salesforce, shareholder, simulation, SOFR, solution, South, suggest, Switzerland, thereon, thereto, therewith, threshold, tier, tiered, TSR, Ukraine, undiscounted, unpaid, unrestricted, upfront, vehicle, weighted, Zealand
Removed:
acceleration, acceptability, adding, adhering, allocated, anesthesiologist, appointed, apportioned, assumed, ASU, biologic, Bipartisan, brand, cancelled, cavity, Center, certified, classifying, committed, concur, corrective, determinable, dual, effected, enrolled, estimating, exchanged, expanded, FASB, faster, feasible, framework, Freestanding, freeze, fullest, implanted, impurity, inaccurately, indemnification, indemnified, inform, infused, injected, Innovation, innovative, instilled, Institute, intention, issuable, ix, led, lessee, leverage, licensure, liquidity, locality, lost, maximum, memorandum, methodology, mitigate, nondeductible, nonqualified, noted, opening, optional, Originally, outpatient, oversee, par, persist, pool, postpone, poverty, preceding, prematurely, presence, preventive, prime, principle, proportionately, proscribed, ramp, ratably, rating, reached, recognizing, reconsider, remained, remediated, removing, reposition, resumption, retroactively, risky, ruling, safest, scenario, seasonal, separation, SPAC, speculative, split, subjected, Subtopic, successor, suffered, underwritten, unnecessarily, vi, vii, viii, withdrawn, worked
Current reports
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 22
8-K
Regulation FD Disclosure
25 May 22
8-K
Impel PHARMACEUTICALS Announces first Quarter 2022 Financial Results and Provides CORPORATE Update
16 May 22
8-K
Amendments to Articles of Incorporation or Bylaws
26 Apr 22
8-K
Regulation FD Disclosure
14 Apr 22
8-K
Impel NeuroPharma Announces FOURTH Quarter AND fULL YEAR 2021 Financial Results and Provides CORPORATE Update
24 Mar 22
8-K
Entry into a Material Definitive Agreement
17 Mar 22
8-K
Impel NeuroPharma Provides Updates on TrudhesaTM Launch
18 Jan 22
8-K
Impel NeuroPharma Announces THIRD Quarter 2021 Financial Results and Provides CORPORATE Update
15 Nov 21
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
1 Oct 21
Registration and prospectus
424B5
Prospectus supplement for primary offering
24 May 22
S-3
Shelf registration
16 May 22
S-8
Registration of securities for employees
29 Mar 22
424B4
Prospectus supplement with pricing info
10 Sep 21
S-1
IPO registration
7 Sep 21
DRS
Draft registration statement
24 Aug 21
S-8
Registration of securities for employees
23 Apr 21
424B1
Prospectus with pricing info
23 Apr 21
8-A12B
Registration of securities on exchange
19 Apr 21
S-1/A
IPO registration (amended)
19 Apr 21
Other
EFFECT
Notice of effectiveness
25 May 22
CORRESP
Correspondence with SEC
19 May 22
UPLOAD
Letter from SEC
19 May 22
EFFECT
Notice of effectiveness
10 Sep 21
CORRESP
Correspondence with SEC
6 Sep 21
CORRESP
Correspondence with SEC
6 Sep 21
UPLOAD
Letter from SEC
29 Aug 21
EFFECT
Notice of effectiveness
23 Apr 21
CERT
Certification of approval for exchange listing
21 Apr 21
CORRESP
Correspondence with SEC
19 Apr 21
Ownership
4
IMPEL PHARMACEUTICALS / Diane E. Wilfong ownership change
17 Jun 22
4
IMPEL PHARMACEUTICALS / MAHENDRA SHAH ownership change
17 Jun 22
4
IMPEL PHARMACEUTICALS / TIMOTHY S NELSON ownership change
17 Jun 22
4
IMPEL PHARMACEUTICALS / H STEWART PARKER ownership change
17 Jun 22
4
IMPEL PHARMACEUTICALS / David D. Allison ownership change
17 Jun 22
4
IMPEL NEUROPHARMA / STEPHEN B SHREWSBURY ownership change
30 Mar 22
4
IMPEL NEUROPHARMA / STEPHEN B SHREWSBURY ownership change
28 Jan 22
4
IMPEL NEUROPHARMA / Leonard Paolillo ownership change
28 Jan 22
4
IMPEL NEUROPHARMA / John Harold Leaman ownership change
28 Jan 22
4
IMPEL NEUROPHARMA / John Hoekman ownership change
28 Jan 22
Patents
Utility
Respiratory Tract Delivery of Levodopa and Dopa Decarboxylase Inhibitor for Treatment of Parkinson's Disease
28 Jul 22
A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome.
Utility
Intranasal device with inlet interface
26 Jul 22
A device for delivering a compound to the olfactory region of the nasal cavity includes an actuator body and a tip that removably couples to the actuator body.
Utility
Nasal Drug Delivery Device
24 Mar 22
A nasal drug delivery device for delivering a plume derived from a propellant and a drug compound.
Utility
Intranasal delivery of olanzapine by precision olfactory device
22 Mar 22
Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours.
Utility
In-line nasal delivery device
8 Mar 22
A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.
Reddit threads
Daily Discussion Thread - August 12th, 2022
12 Aug 22
What Are Your Moves Tomorrow - July 06, 2022
5 Jul 22
FIVE STOCKS YOU LIKE
20 Jun 22
Daily Discussion Thread - May 16th, 2022
16 May 22
Daily Discussion Thread - May 13th, 2022
13 May 22
Daily Discussion Thread - March 24th, 2022
24 Mar 22
Daily Discussion Thread - March 23rd, 2022
23 Mar 22
Daily Discussion Thread - March 22nd, 2022
22 Mar 22
Daily Discussion Thread - March 21st, 2022
21 Mar 22
Daily Discussion Thread - March 18th, 2022
18 Mar 22